Illumina (ILMN) is expected to see growth in earnings, despite facing several challenges, including a significant drop in share value over the past five years. Partnerships with
Ovation.io and
Tempus are aimed at advancing precision medicine and accelerating new therapy development through genomic AI innovation. However, the firm is also under fire, with ongoing class action lawsuits and a critical commentary from expert investor
Jim Cramer labeling it as a 'challenged company'. Recently, the international revenue performance and decreasing stock prices were also scrutinized, due in part to an import ban by
China and unfavorable economic conditions. There is positive news for Illumina with the launch of new technologies, including a spatial transcriptomics technology and multiomic research tools. Moreover, the company has expectations for an adjusted EPS of roughly $4.50 for FY25. However, risks are still present for investors, as seen by the recent dive in share prices.
Illumina ILMN News Analytics from Mon, 28 Oct 2024 07:00:00 GMT to Sat, 03 May 2025 02:13:32 GMT -
Rating -4
- Innovation 5
- Information 6
- Rumor -2
